沈阳医学院学报2024，Vol.26Issue(3)：304-308,5.DOI:10.16753/j.cnki.1008-2344.2024.03.015
原发性中枢神经系统淋巴瘤的治疗进展
Advances in the treatment of primary central nervous system lymphoma
周鹏超 1王晓毅 2于洁2
作者信息
- 1. 滨州医学院研究生院,山东 烟台 264003
- 2. 威海市立医院血液科
- 折叠
摘要
Abstract
Primary central nervous system lymphoma(PCNSL)is an aggressive extranodal non-Hodgkin's lymphoma involving cerebrospinal fluid,medulla spinalis,intraocular structures,cranial nerves,and pia.It is an infiltrating malignant tumor with no involvement outside the central nervous system.PCNSL is sensitive to radiotherapy and chemotherapy,and treatment includes high-dose methotrexate-based remission induction,surgery and consolidation therapy with whole-brain radiotherapy.In recent years,some new drugs,including Bruton tyrosine kinase inhibitor,programmed cell death protein-1 inhibitor,lenalidomide,rituximab,pemetrexed,chimeric antigen receptor T-cell immunotherapy and selective inhibitor of nuclear export,have entered clinical trials or use stage and shown good therapeutic effect.This article reviews the traditional treatment programs of PCNSL patients and summarizes the latest progress of treatment.关键词
原发性中枢神经系统淋巴瘤/甲氨蝶呤/新药Key words
primary central nervous system lymphoma/methotrexate/new drugs分类
医药卫生引用本文复制引用
周鹏超,王晓毅,于洁..原发性中枢神经系统淋巴瘤的治疗进展[J].沈阳医学院学报,2024,26(3):304-308,5.
